Durect, Endo extend Chronogesic pact

By Ted A. Knutson

Washington, Jan. 25 - Durect Corp. said Endo Pharmaceuticals Inc. has agreed to extend its right to terminate their development, commercialization and supply license agreement for the Chronogesic product candidate in the United States and Canada to March 31, 2007 from Jan. 1, 2006.

Under the revised pact, Endo has the right to terminate the development agreement if Durect has not delivered to Endo by that later date a written notice that a human pharmacokinetic trial had been completed with Chronogesic together with a full study report of the results of the trial.

Under the revised development agreement, Endo is responsible for any development costs for Chronogesic prior to May 1, 2007. Starting on that date, Endo will fund 50% of the ongoing development costs for the drug.

Chronogesic is a subcutaneous implant that is intended to continuously deliver sufentanil, an opioid medication, for an extended duration.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

Based in Cupertino, Calif., Durect is an emerging pharmaceuticals company.

Chadds Ford, Pa.-based Endo markets generic and branded drugs, including pain medications such as Percocet and Percodan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.